Osivax Announces Clinical and Preclinical Vaccine Data Presentations at Upcoming Global Influenza Conferences Influenza vaccine candidate OVX836 safety profile and efficacy signals from Phase 2a dose-optimization study to be presented at UIV 2022 Preclinical proof of cross-protection against SARS-COV-2 with OVX033 in hamster challenge model to be presented at Options XI Additional results on the …
Author Archives: osivax
Options XI – for the Control of Influenza
Belfast – Oral Presentation and PostersAlexandre Le Vert, Chief Executive Officer and Co-founder of Osivax, to provide preclinical results obtained with OVX033 as part of a presentation entitled “OVX033, T-cell based vaccine targeting the nucleocapsid provides broad-spectrum protection against SARS-COV-2 VoC in Hamster challenge model”. Two more posters entitled “Results of a phase 2 study with …
Continue reading “Options XI – for the Control of Influenza”
UIV 2022 – Universal Influenza Vaccines
Oxford – Oral PresentationAlexandre Le Vert, Chief Executive Officer and Co-founder of Osivax, to provide latest clinical results obtained with OVX836 as part of a presentation entitled “Results of a phase 2 study with OVX836 suggest effectiveness in preventing Influenza-Like Illness and confirm good safety profile”.
Osivax Secures EUR 10M Grant from Bpifrance to Support Clinical Development of OVX836, a Broad-Spectrum Influenza Vaccine
Osivax Secures EUR 10M Grant from Bpifrance to Support Clinical Development of OVX836, a Broad-Spectrum Influenza Vaccine Lyon, France – June 23, 2022 – Osivax, a biopharmaceutical company developing vaccines to provide broad-spectrum protection against highly mutating infectious viruses and diseases, today announced that it has secured EUR 10M from Bpifrance to support the further clinical development of …
Osivax Provides Clinical Development Update on Lead Influenza Vaccine Candidate OVX836
Osivax Provides Clinical Development Update on Lead Influenza Vaccine Candidate OVX836 Excellent safety continues to be observed in ongoing Phase 2a dose optimization study (OVX836-003) Phase 2a dose optimization study extended to elderly population cohort (OVX836-003) Additional Phase 2a trial combining OVX836 with conventional quadrivalent influenza vaccine (QIV) initiated with first participants enrolled in Australia …
Osivax Enters Research Collaboration with the NIAID for the Evaluation of Combination Approach to Broad-Spectrum Influenza Vaccines
Osivax Enters Research Collaboration with the NIAID for the Evaluation of Combination Approach to Broad-Spectrum Influenza Vaccines Lyon, France – May 17, 2022 – Osivax, a biopharmaceutical company developing vaccines to provide broad-spectrum protection against highly mutating infectious viruses and diseases, today announced that it has entered a research collaboration with the National Institute of Allergy and …
Are more powerful vaccines coming? Shots targeting T cells show promise.
Osivax Announces Publication of Phase 2a Trial Results for Influenza Vaccine Candidate OVX836 in Frontiers in Immunology
Data also discussed in context of OVX836 clinical development update presentation at 2022 World Vaccine Congress Lyon, France – April 21, 2022 – Osivax, a biopharmaceutical company developing vaccines to protect against highly mutating infectious diseases, announced today that the Phase 2a results for its broad-spectrum influenza vaccine candidate, OVX836, have been published under the title “Randomized, …
Osivax Appoints Dr. Michael Watson, Former President of Moderna Vaccine Division, to its Board of Directors
Company also announces upcoming presentation of clinical data for its pan-influenza vaccine candidate at World Vaccine Congress Lyon, France – April 14, 2022 – Osivax, a biopharmaceutical company developing vaccines to protect against highly mutating infectious diseases, announced today the appointment of Dr. Michael Watson to its Board of Directors. Dr. Watson brings over 20 years …
World Congress Vaccine Washington
Washington DC – PresentationAlexandre Le Vert, Chief Executive Officer and Co-founder of Osivax, to provide a clinical update on OVX836 as part of a presentation entitled “Clinical Development Update on OVX836 disruptive T-cell vaccin for broad-protection against multiple influenza strains”.